Дудинская Е. Н., Ткачева О. Н. Роль витамина D в развитии артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2012;11(3):77-81.
1. Bollerslev J., Rosen T., Mollerup C.L., et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J Clinl Endocrin & Metab 2009; 94(7): 2255-61.
2. Calvo M.S., Whiting S.J., Barton C.N. Vitamin D intake: a global perspective of current status. J Nutrit 2005; 135(2): 310-6.
3. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutrit 2004; 80(6): 1689-96.
4. Ekmekci A., Abaci N., Ozbey N.C., et al. Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism. J Endocrinol Invest 2009; 32: 611-6.
5. Fiscella K., Franks P. Vitamin d, race, and cardiovascular mortality. Ann fam med 2010; 8(1): 11-8.
6. Forman J.P., Giovannucci E., Holmes M. D., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49(5): 1063-9.
7. Garson-Barre M. The vitamin D 25-Hydroxylase/ Garson-Barre M.// Vitamin D/ eds. Feldman D. San Diego: Academic press 1997; 41-56.
8. Gennari C., Nami R., Gonnelli S. Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Min and Electrol Metab 1995; 21(1–3): 77-81.
9. Grey A., Lucas J., Horne A., et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrin & Metab 2005; 90(4): 2122-6.
10. Grubbs E.G., Rafeeq S., Jimenez C., et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008; 144(6): 852-9.
11. Gupta R.P. CYP3A4 is a human microsomal vitamin D 25-Hydroxylase. J Bone Mineral Research 2004; 19: 680-8.
12. Heaney Robert P., Weaver Connie M. Calcium and vitamin D. Endocrinol Metab Clin N Am 2003; 32: 181-94.
13. Kong J., Qiao G., Zhang Z., et al. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney International 2008; 74(12): 1577-81.
14. Krause R., Buhring M., Hopfenmuller W., et al. Ultraviolet B and blood pressure. The Lancet 1998; 352(9129): 709-10.
15. Li Y.C., Kong J., Wei M., et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Investig 2002; 110(2): 229-38.
16. Li Y.C., Qiao G., Uskokovic M., et al. VitaminD: a negative endocrine regulator of the reninangiotensin system and blood pressure. J Ster Biochem Molec Biol 2004; 89-90: 387-92.
17. Martins D., Wolf M., Pan D., et al. Prevalence of cardiovascular risk factors and the serumlevels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Inter Med 2007; 167(11): 1159-65.
18. McCarron D.A., Pingree P.A., Rubin R.J., et al. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinarycalcium leak. Hypertension 1980; 2(2): 162-8.
19. Pfeifer M., Begerow B., Minne H. W., et al. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrin& Metab 2001; 86(4): 1633-7.
20. Puepet F.H., Agaba E.I., Chuhwak E.K., et al. Primary hyperparathyroidism presenting with severe hypertension in a middle aged Nigerian—a case report. Nig Postgrad Med J 2008; 15(1): 58-60.
21. Resnick L.M. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 1991; 14(6): 505-20.
22. Resnick L.M., Gupta R.K., Bhargava K.K., et al. Cellular ions in hypertension, diabetes, and obesity: a nuclear magnetic resonance spectroscopic study. Hypertension 1991; 17(6), part 2: 951-7.
23. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30(2): 150-6.
24. Rydberg E., Birgander M., Bondeson A.-G. Effect of successful parathyroidectomy on 24-hour ambulatory blood pressure in patients with primary hyperparathyroidism. Intern J Cardiol 2010; 142(1): 15-21.
25. Sambrook P.N., Chen C.J.S., March L., et al. High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Mineral Res 2006; 21(4): 549-55.
26. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27(12): 2813-8.
27. Silverberg S. Vitamin D deficiency and primary hyperparathyroidism. J Bone Min Res 2007; 22(Supplement 2): V100-4.
28. Sugden J.A., Davies J.I., Witham M.D., et al. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabetic Med 2008; 25(3): 320-5.
29. Ullah M., Uwaifo G.I., Nicholas W.C., et al. Does Vitamin D Deficiency Cause Hypertension? Current Evidence from Clinical Studies and Potential Mechanisms. International Journal of Endocrinology, Volume 2010, Article ID 579640.
30. Verhave G., Siegert C.E.H. Role of vitamin D in cardiovascular disease. The Nederland J Med 2010; 68(3): 113-8.
31. Watson K.E., Abrolat M.L., Malone L.L., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96(6): 1755-60.
32. Zemel M.B., Zemel P.C., Bryg R.J., et al. Dietary calcium induces regression of left ventricular hypertrophy in hypertensive non—insulin-dependent diabetic blacks. Am J Hyperten 1990; 3(6): 458-63.
